WallStreetZenWallStreetZen

NASDAQ: ARAY
Accuray Inc Stock Forecast, Predictions & Price Target

Analyst price target for ARAY

Based on 1 analyst offering 12 month price targets for Accuray Inc.
Min Forecast
$9.00+307.24%
Avg Forecast
$9.00+307.24%
Max Forecast
$9.00+307.24%

Should I buy or sell ARAY stock?

Based on 1 analyst offering ratings for Accuray Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARAY stock forecasts and price targets.

ARAY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-13

1 of 1

Forecast return on equity

Is ARAY forecast to generate an efficient return?
Company
N/A
Industry
-0.03%
Market
20.1%

Forecast return on assets

Is ARAY forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

ARAY revenue forecast

What is ARAY's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$463.5M+3.58%
Avg 2 year Forecast
$491.8M+9.89%
Avg 3 year Forecast
$523.6M+17.01%
ARAY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARAY revenue growth forecast

How is ARAY forecast to perform vs Medical Devices companies and vs the US market?
Company
4.94%
Industry
8.7%
Market
9.39%
ARAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARAY vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
ARAY$2.21$9.00+307.24%Strong Buy
SENS$0.42$2.00+380.77%Buy
RCEL$8.87$23.00+159.30%Strong Buy
MASS$5.60N/AN/A
SMLR$25.45N/AN/A

Accuray Stock Forecast FAQ

Is Accuray Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ARAY) stock is to Strong Buy ARAY stock.

Out of 1 analyst, 1 (100%) are recommending ARAY as a Strong Buy, 0 (0%) are recommending ARAY as a Buy, 0 (0%) are recommending ARAY as a Hold, 0 (0%) are recommending ARAY as a Sell, and 0 (0%) are recommending ARAY as a Strong Sell.

If you're new to stock investing, here's how to buy Accuray stock.

What is ARAY's revenue growth forecast for 2024-2026?

(NASDAQ: ARAY) Accuray's forecast annual revenue growth rate of 4.94% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Accuray's revenue in 2024 is $447,482,000.On average, 2 Wall Street analysts forecast ARAY's revenue for 2024 to be $45,964,722,578, with the lowest ARAY revenue forecast at $45,835,803,183, and the highest ARAY revenue forecast at $46,093,641,972. On average, 2 Wall Street analysts forecast ARAY's revenue for 2025 to be $48,766,240,189, with the lowest ARAY revenue forecast at $48,662,112,986, and the highest ARAY revenue forecast at $48,870,367,392.

In 2026, ARAY is forecast to generate $51,924,765,354 in revenue, with the lowest revenue forecast at $51,924,765,354 and the highest revenue forecast at $51,924,765,354.

What is ARAY's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: ARAY) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is ARAY's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ARAY price target, the average ARAY price target is $9.00, with the highest ARAY stock price forecast at $9.00 and the lowest ARAY stock price forecast at $9.00.

The Wall Street analyst predicted that Accuray's share price could reach $9.00 by Feb 13, 2025. The average Accuray stock price prediction forecasts a potential upside of 307.24% from the current ARAY share price of $2.21.

What is ARAY's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: ARAY) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.